Loading
VT
VistaGen Therapeutics, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by COMMODORE CAPITAL LP, was filed 09 Aug 2023.
VistaGen Therapeutics, Inc.: what insiders have been doing
This page follows insider dealings at VistaGen Therapeutics, Inc. as filed with SEC (Form 4), a company from the Healthcare & Pharma sector. From 24 October 2025 to 24 October 2026, the disclosure feed for VistaGen Therapeutics, Inc. logged 2 filings by 2 insiders.
Not one of the filings records a straightforward purchase or sale on the market. Grants and option exercises follow pay plans set in advance, so they reveal less about an insider's own view than a purchase made with personal money.
Over the last twelve months, not one insider purchase of VistaGen Therapeutics, Inc. stock was filed.
With 2 filings in twelve months, the company is quieter than the median of 24 filings across the 3,167 companies we follow on the same exchange. Our records for VistaGen Therapeutics, Inc. go back to 2011, with 11 purchases and 3 sales on the open market in total. In its latest annual report filed with the SEC (10-K, fiscal year ended 31 March 2026), the company reported revenue of 1.3 m USD and net income of -69.7 m USD.
This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
85
Thresholds
n/a
Buy Volume
€17M
11 ops. · all time
Sell Volume
€132,381
3 ops. · all time
Since the insiders bought
- -54.7%Entry US$7.52 · Close at T+365 US$3.41
- -8.7%Entry US$6.00 · Close at T+365 US$5.48
- -6.3%Entry US$5.70 · Close at T+365 US$5.34
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2026FY ended March 2026 · cache
US$0.18
Analyst consensus
2 analysts3.00/5
US$1.00Target US$1.00(+456%)US$1.00
Income statement
RevenueUS$1.3M
EBITDA-US$71.4M-5626% margin
Net income-US$69.7M-5491.3% margin
Valuation
PER (forward)-0.1x
P/Book0.3x
Beta0.33
Balance sheet & cash
Market capUS$8M
Total debtUS$1M
Free Cash Flow-US$66.6M
Debt / Equity3%
Profitability & ownership
ROE-166.5%
ROA-83.2%
% insiders0.4%
% institutions31.1%
Last declaration on 2 July 2026
Declarations85 total
36,818 sharesCommon StockSEC:0001924908-26-000007:0
4,386 shares@ US$0.56268.6% of flowCommon StockSEC:0001998663-26-000002:0
7,541 shares@ US$1.704.5% of flowCommon StockSEC:0001415889-25-018748:0
7,541 shares@ US$1.7014.5% of flowCommon StockSEC:0001415889-25-018755:0
6,617 shares@ US$1.7037.1% of flowCommon StockSEC:0001415889-25-018751:0
4,882 shares@ US$1.7028.7% of flowCommon StockSEC:0001415889-25-018759:0
3,310 shares@ US$2.507532.6% of flowCommon StockSEC:0001415889-25-001402:0
2,592 shares@ US$2.507524.3% of flowCommon StockSEC:0001415889-25-001396:0
4,854 shares@ US$2.95817.9% of flowCommon StockSEC:0001415889-24-019022:0
4,854 shares@ US$2.9585.6% of flowCommon StockSEC:0001415889-24-019020:0
2,671 shares@ US$2.95830.1% of flowCommon StockSEC:0001415889-24-019028:0
3,592 shares@ US$2.95838.6% of flowCommon StockSEC:0001415889-24-019024:0
167 shares@ US$1.7170.3% of flowCommon StockSEC:0001415889-24-000350:0
167 shares@ US$1.7170.1% of flowCommon StockSEC:0001415889-24-000344:0
775,756 shares@ US$23.153100.0% of flowCommon StockSEC:0001493152-23-027352:0
Canonical exit: 5 Nov 2023 (T+90)
167 shares@ US$1.58950.3% of flowCommon StockSEC:0001415889-23-010720:0
167 shares@ US$1.58950.1% of flowCommon StockSEC:0001415889-23-010721:0
167 shares@ US$1.58950.2% of flowCommon StockSEC:0001415889-23-010719:0
5,000 shares@ US$0.08760.2% of flowCommon StockSEC:0001415889-23-000041:0
5,000 shares@ US$0.08760.4% of flowCommon StockSEC:0001415889-23-000043:0
100,000 shares@ US$0.1787100.0% of flowCommon StockSEC:0001415889-22-008937:0
Canonical exit: 16 Nov 2022 (T+90)
300,000 shares@ US$0.169766.9% of flowCommon StockSEC:0001415889-22-008894:0
Canonical exit: 15 Nov 2022 (T+90)
600,000 shares@ US$0.17242.2% of flowCommon StockSEC:0001415889-22-008814:0
Canonical exit: 15 Nov 2022 (T+90)
5,000 shares@ US$0.74832.0% of flowCommon StockSEC:0001415889-22-007687:0
5,000 shares@ US$0.7483.3% of flowCommon StockSEC:0001415889-22-007686:0
25 of 85 declarations
About VistaGen Therapeutics, Inc.
VistaGen Therapeutics, Inc. (NASDAQ: VTGN, United States) is a late clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The company focuses on neuroscience and the development of intranasal product candidates designed to address psychiatric, neurological, and women’s health needs. VistaGen’s core scientific thesis is centered on “nose-to-brain” neurocircuitry and a class of intranasal compounds it calls pherines, which are intended to act rapidly through nasal administration and potentially offer differentiated tolerability versus conventional systemic therapies.
The company’s roots go back to 1998, when it was originally incorporated under an earlier structure before evolving into Vistagen Therapeutics, Inc. in its current form. Over time, VistaGen has transitioned toward a focused clinical pipeline in central nervous system disorders and other high-unmet-need indications. Its lead program is fasedienol, an intranasal candidate in Phase 3 development for the acute treatment of social anxiety disorder. The broader pipeline also includes PH80, a non-hormonal intranasal candidate being developed for moderate to severe vasomotor symptoms associated with menopause, along with additional pherine assets.
Read moreShow less
From a competitive perspective, VistaGen operates in a crowded biopharmaceutical landscape dominated by much larger pharmaceutical and biotech players. Its differentiation lies in its intranasal delivery approach and its focus on underserved psychiatric indications, where faster onset, convenience, and a favorable side-effect profile could be commercially meaningful if clinical data are supportive. At the same time, the investment case remains classic small-cap biotech: high dependence on clinical trial outcomes, ongoing capital needs, and limited revenue visibility until a product is approved and commercialized.
Recent company updates have been centered on the PALISADE Phase 3 program for fasedienol. Throughout 2025 and into 2026, VistaGen reported progress on PALISADE-3 and PALISADE-4, including operational refinements to the ongoing Phase 3 study and guidance that topline data from PALISADE-4 would be expected in the first half of 2026. In April 2026, the company also announced it had received a “Study May Proceed” letter from the FDA for refisolone nasal spray, a non-hormonal, non-systemic Phase 2 candidate for moderate to severe menopause-related hot flashes. In addition, VistaGen disclosed workforce reductions of approximately 20% in March 2026, highlighting continued cost discipline and the importance of capital efficiency.
For investors, VTGN is a speculative U.S.-listed NASDAQ biotech story with a binary profile. Value creation depends heavily on clinical execution across its lead programs, regulatory milestones, and the company’s ability to manage funding needs while advancing its pipeline.
